Univariate analysis of prognostic factors for survival in patients with diffuse large B-cell lymphoma
| Parameters . | Overall survival . | |
|---|---|---|
| Median, mo (95% CI) . | P . | |
| Epstein-Barr virus status | .026 | |
| EBER-positive | 35.8 (0-114.1) | |
| EBER-negative | NR | |
| Age, y | <.001 | |
| 60 y old or younger | NR | |
| Older than 60 y | 44.7 (28.5-60.9) | |
| Performance status | <.001 | |
| ECOG, 0 to 1 | NR | |
| ECOG, 2 to 4 | 20.9 (11.1-30.7) | |
| Ann Arbor stage | <.001 | |
| Limited (I/II) | NR | |
| Advanced (III/IV) | 28.5 (1.8-55.1) | |
| Lactic dehydrogenase | <.001 | |
| ULN or below | NR | |
| Over ULN | 58.8 (20.7-96.9) | |
| No. of extranodal involvement | <.001 | |
| 0 or 1 | NR | |
| 2 or more | 21.1 (12.0-29.1) | |
| B symptom | <.001 | |
| Positive | 54.7 (11.0-98.4) | |
| Negative | NR | |
| Bone marrow involvement | <.001 | |
| Positive | 20.4 (8.2-32.5) | |
| Negative | NR | |
| Histologic subtype | .990 | |
| Nongerminal center B cell–like | NR | |
| Germinal center B cell–like | NR | |
| Primary treatment | <.001 | |
| Anthracycline-based | NR | |
| Non-anthracycline-based | 44.7 (22.9-66.4) | |
| The use of rituximab | .022 | |
| Rituximab | NR | |
| No rituximab | 101.9 | |
| Parameters . | Overall survival . | |
|---|---|---|
| Median, mo (95% CI) . | P . | |
| Epstein-Barr virus status | .026 | |
| EBER-positive | 35.8 (0-114.1) | |
| EBER-negative | NR | |
| Age, y | <.001 | |
| 60 y old or younger | NR | |
| Older than 60 y | 44.7 (28.5-60.9) | |
| Performance status | <.001 | |
| ECOG, 0 to 1 | NR | |
| ECOG, 2 to 4 | 20.9 (11.1-30.7) | |
| Ann Arbor stage | <.001 | |
| Limited (I/II) | NR | |
| Advanced (III/IV) | 28.5 (1.8-55.1) | |
| Lactic dehydrogenase | <.001 | |
| ULN or below | NR | |
| Over ULN | 58.8 (20.7-96.9) | |
| No. of extranodal involvement | <.001 | |
| 0 or 1 | NR | |
| 2 or more | 21.1 (12.0-29.1) | |
| B symptom | <.001 | |
| Positive | 54.7 (11.0-98.4) | |
| Negative | NR | |
| Bone marrow involvement | <.001 | |
| Positive | 20.4 (8.2-32.5) | |
| Negative | NR | |
| Histologic subtype | .990 | |
| Nongerminal center B cell–like | NR | |
| Germinal center B cell–like | NR | |
| Primary treatment | <.001 | |
| Anthracycline-based | NR | |
| Non-anthracycline-based | 44.7 (22.9-66.4) | |
| The use of rituximab | .022 | |
| Rituximab | NR | |
| No rituximab | 101.9 | |
ULN indicates upper limit normal; NR, not reached.